Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

4-(3,5-bis-(hydroxy-phenyl)-1,2,4) triazol-1-yl)-benzoic acid

EU orphan designation number: EU/3/02/092   
Active ingredient: 4-(3,5-bis-(hydroxy-phenyl)-1,2,4) triazol-1-yl)-benzoic acid
Indication: Treatment of chronic iron overload requiring chelation therapy
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Exjade on 28/08/2006 with the number EU/1/06/356

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/03/2002 Centralised Orphan - Designation EMEA/OD/061/01 (2002)1128 of 13/03/2002
29/08/2014 Centralised Orphan - Change of address